Verastem, Inc.

Stocks

VSTM

US92337C2035

Real-time Estimate Cboe BZX 16:01:14 2026-10-30 EDT			5-day change	1st Jan Change
9.920 ^USD	+2.69%		-2.39%	+26.94%

10-15	Verastem's G12D Drug Shows Promise in Pancreatic Cancer, Shares Undervalued, RBC Says	MT
10-15	Mizuho Raises Price Target on Verastem to $14 From $13, Keeps Outperform Rating	MT

Transcript : Verastem, Inc. - Special Call

Published on 10/14/2026 at 10:37 am EDT - Modified on 10/14/2026 at 07:03 pm EDT

S&P Capital IQ

Presenter Speech
Julissa Viana (Executives)

Good morning, everyone. For those that don't know me, I'm Julissa Viana, the Senior Vice President of Corporate Communications, Investor Relations and

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Verastem, Inc.

10-15	Verastem's G12D Drug Shows Promise in Pancreatic Cancer, Shares Undervalued, RBC Says	MT
10-15	Mizuho Raises Price Target on Verastem to $14 From $13, Keeps Outperform Rating	MT
10-15	RBC Raises Price Target on Verastem to $19 From $14, Keeps Outperform, Speculative Risk	MT
10-15	GenFleet's Oral Cancer Drug Enters Phase III Testing in China; Shares Up 3%	MT
10-14	Verastem, Inc. - Special Call
10-14	Verastem Oncology Announces Management Changes	CI
10-14	Verastem Oncology Announces CEO Changes, Effective January 1, 2027	CI
10-14	Verastem Oncology Announces Positive Initial Efficacy And Updated Safety And Tolerability Data For VS-7375 In Ongoing TARGET-D 101 Phase 1/2 Clinical Trial	CI
10-14	Verastem Cancer Drug Shows Responses in Pancreatic, Lung, and Colorectal Cancers	MT
10-14	Verastem Oncology Names Michael Bailey CEO; Prices $250 Million Offering -- Shares Rise Pre-Bell	MT
10-07	B. Riley Adjusts Verastem Price Target to $19 From $16, Maintains Buy Rating	MT
09-28	Verastem Oncology Announces Publication Of Two-Year Long-Term Results From Phase 2 RAMP 201 Study Evaluating AVMAPKI FAKZYNJA CO-PACK In Recurrent Low-Grade Serous Ovarian Cancer	CI
09-18	Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says	MT
09-17	Wolfe Research Initiates Verastem at Outperform	MT
09-14	RTW Biotech NAV rises 15% as public investments drive returns	AN

Chart Verastem, Inc.

Duration

Period

VSTM: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

Projected Income Statement - Annual - Verastem, Inc.

More financial data

Ratings

More Ratings

EPS Estimates

Evolution of Analysts' Estimates - EPS - Verastem, Inc.

Revisions to estimates